Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.43 |
| ▸ | SLC22A2 | O15244 | 8/20 | 0.42 |
| ▸ | HTR2C | P28335 | 2/20 | 0.41 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3525978 | 0.92 | KMT2A (0.47) | MAPTSLC22A2 | |
| SCHEMBL2184805 | 0.89 | SLC22A2 (0.44) | MAPTSLC22A2LIPGSMN1; SMN2 | |
| SCHEMBL3524314 | 0.88 | LMNA (0.47) | MAPTSLC22A2 | |
| SCHEMBL3520763 | 0.86 | TP53 (0.49) | SLC22A2 | |
| SCHEMBL82568 | 0.86 | LIPG (0.46) | MAPTSLC22A2LIPGSMN1; SMN2 | |
| SCHEMBL22482699 | 0.86 | MAPT (0.44) | MAPTSLC22A2LIPGSMN1; SMN2 | |
| SCHEMBL2187466 | 0.86 | LIPG (0.44) | MAPTSLC22A2LIPGSMN1; SMN2 | |
| SCHEMBL2187383 | 0.85 | MAPT (0.43) | MAPTSLC22A2LIPGSMN1; SMN2 | |
| SCHEMBL2237584 | 0.85 | KMT2A (0.48) | MAPTSLC22A2LIPG | |
| SCHEMBL3528935 | 0.85 | MAPT (0.43) | MAPTSLC22A2LIPGRXFP1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1950212-B1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING INHIBITORY ACTIVITY ON HIV INTEGRASE | SHIONOGI & CO (JP) | 2016-02-24 | — | — | EP | disclosed |
| US-20120208998-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | YOSHIDA HIROSHI (JP) | 2012-08-16 | — | — | US | disclosed |
| US-8188271-B2 | Polycyclic carbamoylpyridone derivative having HIV integrase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2012-05-29 | — | — | US | disclosed |
| US-7858788-B2 | Bicyclic carbamoylpyridone derivative having HIV integrase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2010-12-28 | — | — | US | disclosed |
| US-20090143356-A1 | Polycylclic Carbamoylpyridone Derivative Having HIV Integrase Inhibitory Acitvity | SHIONOGI & CO., LTD. (JP) | 2009-06-04 | — | — | US | disclosed |
| EP-1950212-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING INHIBITORY ACTIVITY ON HIV INTEGRASE | Shionogi Co., Ltd. (JP) | 2008-07-30 | — | — | EP | disclosed |
| US-20080161271-A1 | Bicyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity | SHIONOGI & CO., LTD. (JP) | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161271-A1 | Bicyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity | NR4A1, HAT1, NR4A2 | MAPT 4715/4885MCHR1 4576/4885SLC22A2 2858/4885 |
| US-20120208998-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | CDKN1A, CDK2, CDK2AP1 | MAPT 2144/4885MCHR1 4674/4885SLC22A2 4007/4885 |
| US-20090143356-A1 | Polycylclic Carbamoylpyridone Derivative Having HIV Integrase Inhibitory Acitvity | CDK20, CYP4A22, CDK10 | MAPT 4110/4885MCHR1 2995/4885SLC22A2 503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.